Gender differences in thyroid system function: Relevance to bipolar disorder and its treatment

Bipolar Disorders

Volumn 16, Issue 1, 2014, Pages 58-71

  Bauer, Michael ^a   Glenn, Tasha ^b   Pilhatsch, Maximilian ^a   Pfennig, Andrea ^a   Whybrow, Peter C ^c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b ChronoRecord Association Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bipolar disorder; Depression; Gender differences; Thyroid hormone; Thyroid system

Indexed keywords

ESTROGEN; IODINE; LIOTHYRONINE; LITHIUM; PSYCHOTROPIC AGENT; THYROID HORMONE; THYROXINE; TOXIN;

ADULT DISEASE; AGE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BIPOLAR DISORDER; BRAIN; DISEASE ASSOCIATION; DISEASE COURSE; HORMONE SUBSTITUTION; HUMAN; LABORATORY DIAGNOSIS; MOOD DISORDER; POSTMENOPAUSE; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHIATRIC TREATMENT; REVIEW; SEX DIFFERENCE; SUBCLINICAL HYPOTHYROIDISM; THYROID DISEASE; THYROID FUNCTION; THYROID GLAND METABOLISM; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE;

BIPOLAR DISORDER; DEPRESSION; GENDER DIFFERENCES; THYROID HORMONE; THYROID SYSTEM;

BIPOLAR DISORDER; FEMALE; HUMANS; MALE; SEX CHARACTERISTICS; THYROID GLAND;

EID: 84893040638     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12150     Document Type: Review

References (134)

1. Vanderpump MP, Tunbridge WM, French JM et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43: 55-68.
2. Hollowell JG, Staehling NW, Flanders WD et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489-499.
3. Whybrow PC. Sex differences in thyroid axis function: relevance to affective disorder and its treatment. Depression 1995; 3: 33-42.
4. Bauer M, Goetz T, Glenn T, Whybrow PC. The thyroid-brain interaction in thyroid disorders and mood disorders. J Neuroendocrinol 2008; 20: 1101-1114.
5. Bauer M, Samuels MH, Whybrow PC. Behavioral and psychiatric aspects of thyrotoxicosis. In: Braverman LE, Cooper DS eds. Werner & Ingbar's The Thyroid. A Fundamental and Clinical Text, 10th edn. Wolters Kluwer Health, Lippincott Williams & Wilkins, Philadelphia, PA, 2013: 475-480.
6. Schuff KG, Samuels MH, Whybrow PC, Bauer M. Psychiatric and cognitive effects of hypothyroidism. In: Braverman LE, Cooper DS eds. Werner & Ingbar's The Thyroid. A Fundamental and Clinical Text, 10th edn. Wolters Kluwer Health, Lippincott Williams & Wilkins, Philadelphia, PA, 2013: 596-600.
7. Piccinelli M, Wilkinson G. Gender differences in depression. Critical review. Br J Psychiatry 2000; 177: 486-492.
8. Bauer MS, Whybrow PC, Winokur A. Rapid cycling bipolar affective disorders. I. Association with grade I hypothyroidism. Arch Gen Psychiatry 1990; 47: 427-432.
9. Bauer M, Beaulieu S, Dunner DL, Lafer B, Kupka R. Rapid cycling bipolar disorder - diagnostic concepts. Bipolar Disord 2008; 10: 153-162.
10. Bauer M, Heinz A, Whybrow PC. Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. Mol Psychiatry 2002; 7: 140-156.
11. Oetting A, Yen PM. New insights into thyroid hormone action. Best Pract Res Clin Endocrinol Metab 2007; 21: 193-208.
12. Leonard JL. Regulation of T3 production in the brain. Acta Med Austriaca 1992; 19 (Suppl. 1): 5-8.
13. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med 2003; 348: 2646-2655.
14. Cooper DS. Hyperthyroidism. Lancet 2003; 362: 459-468.
15. Baloch Z, Carayon P, Conte-Devolx B et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003; 13: 3-126.
16. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008; 29: 76-131.
17. Surks MI, Ortiz E, Daniels GH et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228-238.
18. Sinclair D. Clinical and laboratory aspects of thyroid autoantibodies. Ann Clin Biochem 2006; 43: 173-183.
19. Whybrow PC, Prange AJ Jr, Treadway CR. Mental changes accompanying thyroid gland dysfunction. Arch Gen Psychiatry 1969; 20: 48-63.
20. Garber JR, Cobin RH, Gharib H et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 2012; 22: 1200-1235.
21. Miller KJ, Parsons TD, Whybrow PC et al. Verbal memory retrieval deficits associated with untreated hypothyroidism. J Neuropsychiatry Clin Neurosci 2007; 19: 132-136.
22. Burmeister LA, Ganguli M, Dodge HH, Toczek T, DeKosky ST, Nebes RD. Hypothyroidism and cognition: preliminary evidence for a specific defect in memory. Thyroid 2001; 11: 1177-1185.
23. Osterweil D, Syndulko K, Cohen SN et al. Cognitive function in non-demented older adults with hypothyroidism. J Am Geriatr Soc 1992; 40: 325-335.
24. Haupt M, Kurz A. Reversibility of dementia in hypothyroidism. J Neurol 1993; 240: 333-335.
25. Wekking EM, Appelhof BC, Fliers E et al. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur J Endocrinol 2005; 153: 747-753.
26. Samuels MH, Schuff KG, Carlson NE, Carello P, Janowsky JS. Health status, psychological symptoms, mood, and cognition in L-thyroxine-treated hypothyroid subjects. Thyroid 2007; 17: 249-258.
27. Boucai L, Surks MI. Reference limits of serum TSH and free T4 are significantly influenced by race and age in an urban outpatient medical practice. Clin Endocrinol 2009; 70: 788-793.
28. Thienpont LM, Van Uytfanghe K, Beastall G et al. Report of the IFCC Working Group for Standardization of Thyroid Function Tests; part 1: thyroid-stimulating hormone. Clin Chem 2010; 56: 902-911.
29. Hoogendoorn EH, Hermus AR, de Vegt F et al. Thyroid function and prevalence of anti-thyroperoxidase antibodies in a population with borderline sufficient iodine intake: influences of age and sex. Clin Chem 2006; 52: 104-111.
30. Panicker V, Wilson SG, Spector TD et al. Heritability of serum TSH, free T4 and free T3 concentrations: a study of a large UK twin cohort. Clin Endocrinol 2008; 68: 652-659.
31. Karmisholt J, Andersen S, Laurberg P. Variation in thyroid function tests in patients with stable untreated subclinical hypothyroidism. Thyroid 2008; 18: 303-308.
32. Karmisholt J, Andersen S, Laurberg P. Variation in thyroid function in subclinical hypothyroidism: importance of clinical follow-up and therapy. Eur J Endocrinol 2011; 164: 317-323.
33. Stagnaro-Green A, Abalovich M, Alexander E et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011; 21: 1081-1125.
34. Dickerman AL, Barnhill JW. Abnormal thyroid function tests in psychiatric patients: a red herring? Am J Psychiatry 2012; 169: 127-133.
35. Nader S, Warner MD, Doyle S, Peabody CA. Euthyroid sick syndrome in psychiatric inpatients. Biol Psychiatry 1996; 40: 1288-1293.
36. Huber G, Staub JJ, Meier C et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab 2002; 87: 3221-3226.
37. Díez JJ, Iglesias P. Spontaneous subclinical hypothyroidism in patients older than 55 years: an analysis of natural course and risk factors for the development of overt thyroid failure. J Clin Endocrinol Metab 2004; 89: 4890-4897.
38. Walsh JP, Bremner AP, Feddema P, Leedman PJ, Brown SJ, O'Leary P. Thyrotropin and thyroid antibodies as predictors of hypothyroidism: a 13-year, longitudinal study of a community-based cohort using current immunoassay techniques. J Clin Endocrinol Metab 2010; 95: 1095-1104.
39. Bjoro T, Holmen J, Krüger O et al. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). Eur J Endocrinol 2000; 143: 639-647.
40. O'Leary PC, Feddema PH, Michelangeli VP et al. Investigations of thyroid hormones and antibodies based on a community health survey: the Busselton thyroid study. Clin Endocrinol 2006; 64: 97-104.
41. Roberts CG, Ladenson PW. Hypothyroidism. Lancet 2004; 363: 793-803.
42. Meier C, Trittibach P, Guglielmetti M, Staub JJ, Müller B. Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with overt primary thyroid failure: cross sectional survey. BMJ 2003; 326: 311-312.
43. Meier C, Staub JJ, Roth CB et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001; 86: 4860-4866.
44. Kharlip J, Cooper DS. Recent developments in hyperthyroidism. Lancet 2009; 373: 1930-1932.
45. Collet TH, Gussekloo J, Bauer DC et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012; 172: 799-809.
46. Selmer C, Olesen JB, Hansen ML et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ 2012; 345: e7895.
47. Devdhar M, Drooger R, Pehlivanova M, Singh G, Jonklaas J. Levothyroxine replacement doses are affected by gender and weight, but not age. Thyroid 2011; 21: 821-827.
48. Escobar-Morreale HF, Botella-Carretero JI, Escobar del Rey F, Morreale de Escobar G. Treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. J Clin Endocrinol Metab 2005; 90: 4946-4954.
49. Panicker V, Saravanan P, Vaidya B et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab 2009; 94: 1623-1629.
50. Hannemann A, Friedrich N, Haring R et al. Thyroid function tests in patients taking thyroid medication in Germany: results from the population-based Study of Health in Pomerania (SHIP). BMC Res Notes 2010; 3: 227.
51. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160: 526-534.
52. Okosieme OE, Belludi G, Spittle K, Kadiyala R, Richards J. Adequacy of thyroid hormone replacement in a general population. QJM 2011; 104: 395-401.
53. Crilly M, Esmail A. Randomised controlled trial of a hypothyroid educational booklet to improve thyroxine adherence. Br J Gen Pract 2005; 55: 362-368.
54. Barbesino G. Drugs affecting thyroid function. Thyroid 2010; 20: 763-770.
55. Leibenluft E. Women with bipolar illness: clinical and research issues. Am J Psychiatry 1996; 153: 163-173.
56. Blehar MC, DePaulo JR Jr, Gershon ES, Reich T, Simpson SG, Nurnberger JI Jr. Women with bipolar disorder: findings from the NIMH Genetics Initiative sample. Psychopharmacol Bull 1998; 34: 239-243.
57. Arnold LM. Gender differences in bipolar disorder. Psychiatr Clin North Am 2003; 26: 595-620.
58. Sit D. Women and bipolar disorder across the life span. J Am Med Womens Assoc 2004; 59: 91-100.
59. Burt VK, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disord 2004; 6: 2-13.
60. Barnes C, Mitchell P. Considerations in the management of bipolar disorder in women. Aust N Z J Psychiatry 2005; 39: 662-673.
61. Frye MA, Altshuler LL, McElroy SL et al. Gender differences in prevalence, risk, and clinical correlates of alcoholism comorbidity in bipolar disorder. Am J Psychiatry 2003; 160: 883-889.
62. Parry BL, Newton RP. Chronobiological basis of female-specific mood disorders. Neuropsychopharmacology 2001; 25 (Suppl. 5): S102-S108.
63. Marsh WK, Ketter TA, Crawford SL, Johnson JV, Kroll-Desrosiers AR, Rothschild AJ. Progression of female reproductive stages associated with bipolar illness exacerbation. Bipolar Disord 2012; 14: 515-526.
64. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 2002; 63 (Suppl. 4): 42-55.
65. Viguera AC, Whitfield T, Baldessarini RJ et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007; 164: 1817-1824.
66. Yonkers KA, Wisner KL, Stowe Z et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161: 608-620.
67. Haggerty JJ Jr, Stern RA, Mason GA, Beckwith J, Morey CE, Prange AJ Jr. Subclinical hypothyroidism: a modifiable risk factor for depression? Am J Psychiatry 1993; 150: 508-510.
68. Bunevicius R, Prange AJ Jr. Thyroid disease and mental disorders: cause and effect or only comorbidity? Curr Opin Psychiatry 2010; 23: 363-368.
69. Musselman DL, Nemeroff CB. Depression and endocrine disorders: focus on the thyroid and adrenal system. Br J Psychiatry Suppl 1996; 30: 123-128.
70. Cole DP, Thase ME, Mallinger AG et al. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry 2002; 159: 116-121.
71. Frye MA, Denicoff KD, Bryan AL et al. Association between lower serum free T4 and greater mood instability and depression in lithium-maintained bipolar patients. Am J Psychiatry 1999; 156: 1909-1914.
72. Gyulai L, Bauer M, Bauer MS, García-España F, Cnaan A, Whybrow PC. Thyroid hypofunction in patients with rapid-cycling bipolar disorder after lithium challenge. Biol Psychiatry 2003; 53: 899-905.
73. Krausz Y, Freedman N, Lester H et al. Brain SPECT study of common ground between hypothyroidism and depression. Int J Neuropsychopharmacol 2007; 10: 99-106.
74. Bauer M, Silverman DH, Schlagenhauf F et al. Brain glucose metabolism in hypothyroidism: a positron emission tomography study before and after thyroid hormone replacement therapy. J Clin Endocrinol Metab 2009; 94: 2922-2929.
75. Bauer M, London ED, Rasgon N et al. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in women with bipolar depression. Mol Psychiatry 2005; 10: 456-469.
76. Goodwin FK, Jamison KR. Manic-Depressive Illness, 2nd edn. New York, NY: Oxford University Press, 2007.
77. Grunze H, Vieta E, Goodwin GM et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010; 11: 81-109.
78. Altshuler LL, Bauer M, Frye MA et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001; 158: 1617-1622.
79. Coppen A, Whybrow PC, Noguera R, Maggs R, Prange AJ Jr. The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatry 1972; 26: 234-241.
80. Wheatley D. Potentiation of amitriptyline by thyroid hormone. Arch Gen Psychiatry 1972; 26: 229-233.
81. Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 1996; 53: 842-848.
82. Agid O, Lerer B. Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. Int J Neuropsychopharmacol 2003; 6: 41-49.
83. Appelhof BC, Brouwer JP, Van Dyck R et al. Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. J Clin Endocrinol Metab 2004; 89: 6271-6276.
84. Cooper-Kazaz R, Apter JT, Cohen R et al. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2007; 64: 679-688.
85. Abraham G, Milev R, Lawson JS. T3 augmentation of SSRI resistant depression. J Affect Disord 2006; 91: 211-215.
86. 3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163: 1519-1530.
87. Baumgartner A, Bauer M, Hellweg R. Treatment of intractable non-rapid cycling bipolar affective disorder with high-dose thyroxine: an open clinical trial. Neuropsychopharmacology 1994; 10: 183-189.
88. Bauer M, Berghöfer A, Bschor T et al. Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis resistant affective disorders. Neuropsychopharmacology 2002; 27: 620-628.
89. Stancer HC, Persad E. Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Arch Gen Psychiatry 1982; 39: 311-312.
90. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder: II. Treatment of refractory rapid cycling with high-dose levothyroxine: preliminary study. Arch Gen Psychiatry 1990; 47: 435-440.
91. Hurowitz GI, Liebowitz MR. Antidepressant-induced rapid cycling: six case reports. J Clin Psychopharmacol 1993; 13: 52-56.
92. Leibow D. L-thyroxine for rapid-cycling bipolar illness. Am J Psychiatry 1983; 140: 1255-1256.
93. Bauer M, Hellweg R, Graf K-J, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 1998; 18: 444-455.
94. Rudas S, Schmitz M, Pichler P, Baumgartner A. Treatment of refractory chronic depression and dysthymia with high-dose thyroxine. Biol Psychiatry 1999; 45: 229-233.
95. Lojko D, Rybakowski JK. L-Thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. J Affect Disord 2007; 103: 253-256.
96. Stamm TJ, Lewitizka U, Sauer C et al. Supraphysiological doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double blind, placebo-controlled study. J Clin Psychiatry 2013. in press
97. Gyulai L, Bauer M, Garcia-Espana F et al. Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation. J Affect Disord 2001; 66: 185-191.
98. Bauer M, Fairbanks L, Berghöfer A et al. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study. J Affect Disord 2004; 83: 183-190.
99. Ricken R, Bermpohl F, Schlattmann P et al. Long-term treatment with supraphysiological doses of thyroid hormone in affective disorders - effects on bone mineral density. J Affect Disord 2012; 136: e89-e94.
100. Halbreich U, Palter S. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull 1996; 22: 447-454.
101. Bülow Pedersen I, Knudsen N, Jørgensen T et al. Large differences in incidences of overt hyper- and hypothyroidism associated with a small difference in iodine intake: a prospective comparative register-based population survey. J Clin Endocrinol Metab 2002; 87: 4462-4469.
102. Laurberg P, Bülow Pedersen I, Knudsen N, Ovesen L, Andersen S. Environmental iodine intake affects the type of nonmalignant thyroid disease. Thyroid 2001; 11: 457-469.
103. Dunn JT. What's happening to our iodine? J Clin Endocrinol Metab 1998; 83: 3398-3400.
104. Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23: 723-733.
105. Kupka RW, Nolen WA, Post RM et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry 2002; 51: 305-311.
106. Bauer M, Blumentritt H, Finke R et al. Using ultrasonography to determine thyroid size and prevalence of goiter in lithium-treated patients with affective disorders. J Affect Disord 2007; 104: 45-51.
107. Kirov G, Tredget J, John R, Owen MJ, Lazarus JH. A cross-sectional and a prospective study of thyroid disorders in lithium-treated patients. J Affect Disord 2005; 87: 313-317.
108. Shulman KI, Sykora K, Gill SS et al. New thyroxine treatment in older adults beginning lithium therapy: implications for clinical practice. Am J Geriatr Psychiatry 2005; 13: 299-304.
109. Bocchetta A, Cocco F, Velluzzi F, Del Zompo M, Mariotti S, Loviselli A. Fifteen-year follow-up of thyroid function in lithium patients. J Endocrinol Invest 2007; 30: 363-366.
110. Lee S, Chow CC, Wing YK, Shek CC. Thyroid abnormalities during chronic lithium treatment in Hong Kong Chinese: a controlled study. J Affect Disord 1992; 26: 173-178.
111. Leutgeb U. Ambient iodine and lithium-associated with clinical hypothyroidism. Br J Psychiatry 2000; 176: 495-496.
112. Markou K, Georgopoulos N, Kyriazopoulou V, Vagenakis AG. Iodine-Induced hypothyroidism. Thyroid 2001; 11: 501-510.
113. Shopsin B, Shenkman L, Blum M, Hollander CS. Iodine and lithium-induced hypothyroidism: documentation of synergism. Am J Med 1973; 55: 695-699.
114. Henry C. Lithium side-effects and predictors of hypothyroidism in patients with bipolar disorder: sex differences. J Psychiatry Neurosci 2002; 27: 104-107.
115. Yassa R, Saunders A, Nastase C, Camille Y. Lithium-induced thyroid disorders: a prevalence study. J Clin Psychiatry 1988; 49: 14-16.
116. Barclay ML, Brownlie BE, Turner JG, Wells JE. Lithium associated thyrotoxicosis: a report of 14 cases, with statistical analysis of incidence. Clin Endocrinol (Oxf) 1994; 40: 759-764.
117. Miller KK, Daniels GH. Association between lithium use and thyrotoxicosis caused by silent thyroiditis. Clin Endocrinol 2001; 55: 501-508.
118. Bandyopadhyay D, Nielsen C. Lithium-induced hyperthyroidism, thyrotoxicosis and mania: a case report. QJM 2012; 105: 83-85.
119. Oakley PW, Dawson AH, Whyte IM. Lithium: thyroid effects and altered renal handling. J Toxicol Clin Toxicol 2000; 38: 333-337.
120. Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004; 63 (Suppl. 4): S3-S8.
121. Benedetti MS, Whomsley R, Baltes E, Tonner F. Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction. Eur J Clin Pharmacol 2005; 61: 863-872.
122. Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry 2005; 66: 80-84.
123. Liappas J, Paparrigopoulos T, Mourikis I, Soldatos C. Hypothyroidism induced by quetiapine: a case report. J Clin Psychopharmacol 2006; 26: 208-209.
124. Tahboub R, Arafah BM. Sex steroids and the thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23: 769-780.
125. Melzer D, Rice N, Depledge MH, Henley WE, Galloway TS. Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey. Environ Health Perspect 2010; 118: 686-692.
126. Lyon JL, Alder SC, Stone MB et al. Thyroid disease associated with exposure to the Nevada nuclear weapons test site radiation: a reevaluation based on corrected dosimetry and examination data. Epidemiology 2006; 17: 604-614.
127. Tunbridge WM, Evered DC, Hall R et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7: 481-493.
128. Leese GP, Flynn RV, Jung RT, MacDonald TM, Murphy MJ, Morris AD. Increasing prevalence and incidence of thyroid disease in Tayside, Scotland: the Thyroid Epidemiology Audit and Research Study (TEARS). Clin Endocrinol 2008; 68: 311-316.
129. Knudsen N, Jørgensen T, Rasmussen S, Christiansen E, Perrild H. The prevalence of thyroid dysfunction in a population with borderline iodine deficiency. Clin Endocrinol 1999; 51: 361-367.
130. Aghini-Lombardi F, Antonangeli L, Martino E et al. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J Clin Endocrinol Metab 1999; 84: 561-566.
131. Camargo RY, Tomimori EK, Neves SC et al. Thyroid and the environment: exposure to excessive nutritional iodine increases the prevalence of thyroid disorders in São Paulo, Brazil. Eur J Endocrinol 2008; 159: 293-299.
132. Konno N, Yuri K, Taguchi H et al. Screening for thyroid diseases in an iodine sufficient area with sensitive thyrotrophin assays, and serum thyroid autoantibody and urinary iodide determinations. Clin Endocrinol (Oxf) 1993; 38: 273-281.
133. Chan AOK, Iu YP, Shek CC. The reference interval of thyroid-stimulating hormone in Hong Kong Chinese. J Clin Pathol 2011; 64: 433-436.
134. Afflelou S, Auriacombe M, Cazenave M, Chartres JP, Tignol J. Administration of high dose levothyroxine in treatment of rapid cycling bipolar disorders. Review of the literature and initial therapeutic application apropos of 6 cases (in French). Encephale 1997; 23: 209-217.